KETABET™, a patented combination formulation of FDA-approved ketamine and betaine anhydrous, has been shown in research to enhance the antidepressant effect while having the potential to reduce the ...
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella ...
Trial Did Not Meet Primary Endpoint Believed to be the Result of BOTOX Not Effectively Permeating the Urothelium RTGel Delivered Treatment to the Bladder as Expected with Dwell Time of Up to 10 Hours ...
"The IV formulation of DARZALEX, which is approved in combination with pomalidomide and dexamethasone, is an important option for patients with multiple myeloma. We are excited to pursue the ...
Tumor targeting and intratumoral penetration are longstanding issues for cancer therapeutics. Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences and the ...
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 The application is supported by ...
April 6, 2007 — Results of 2 randomized studies assessing a fixed-dose tablet combining sumatriptan and naproxen ( Trexima, Pozen Inc/GlaxoSmithKline) suggest that the combination offers more ...
Acrux (ASX: ACR) -- The Australian drug delivery company, today announced positive results from its Phase 1 clinical studies using two unique contraceptive skin sprays, each containing a progestin and ...
Wu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results